We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Israeli Scientist to Develop "Electronic Nose”

By Labmedica staff writers
Posted on 08 Nov 2006
Dr. More...
Hossam Haick, of the Technion Faculty of Chemical Engineering and the Russell Berrie Nanotechnology Institute at the Technion (Haifa, Israel), has been awarded an excellence grant totaling U.S.$2.21 million from the European Union (EU) for the development of an artificial olfactory system, or "electronic nose,” that can sniff out cancer.

In its initial stage, the electronic nose is intended to sniff out and diagnose lung cancer. "Realization of the research goal will enable creating an instrument based on nanometer-sized sensors that can diagnose different cancers and even determine at what stage the disease is by using breath samples [i.e., by blowing into the instrument],” explained Dr. Haick. "The diagnosis can be carried out at a very early stage even before the tumor has begun to spread. Thus, treatment will be immediate and will destroy the disease at its inception.”

The grant, named after Marie Curie, was awarded to Dr. Haick as part of EU efforts to strengthen and encourage promising, young scientists. Dr. Haick, a 31-year old scientist born in Nazareth, completed his Ph.D. at the Technion. He recently returned to the institute as a senior lecturer, following his post-doctorate at Caltech California Institute of Technology (Caltech, Pasadena, CA, USA).

"In our research, we already showed that, using nanosensors, it is possible to differentiate between a healthy human being and one with cancer,” said Dr. Haick. "The challenge now before us is to distinguish between the various types of cancer and the disease's stages.” With the grant that he received, plus the additional funds he received from the Technion through the Russell Berrie Nanotechnology Institute, Dr. Haick is setting up a laboratory that will include equipment valued at more than U.S.$1 million and is currently recruiting scientists from Israel and abroad.



Related Links:
Russell Berrie Nanotechnology Institute at the Technion
Caltech California Institute of Technology

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.